Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that’s showing ...

The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...

While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...

Researchers have long known that diet exerts a profound influence on health, including the risk of developing cancer. A new ...

Biological age, rather than chronological age, may be a stronger predictor of colorectal cancer risk—especially in older ...

has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or ...

Turnstone Biologics (NASDAQ:TSBX – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Turnstone Biologics to post ...

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688 ...

Your organs might be aging faster than you are -- and that could increase your risk for serious diseases, including c ...

has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after ...